Across TCGA pan-cancer cohorts, ANAPC7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANAPC7 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ANAPC7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANAPC7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where ANAPC7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.231	0.818	.004	19	view →
CCRCC	OS	Median	All	0.897	0.985	.016	8	view →
UCEC	DFS	Tertile	All	0.947	0.743	.018	8	view →
LSCC	DFS	Median	All	0.975	0.903	.015	3	view →
LUAD	OS	Quartile	II,III,IV	0.317	0.839	.044	2	view →
PDAC	OS	Median	All	0.796	0.890	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: ANAPC7 tumor-vs-normal RNA expression · all ANAPC7 data types